Q-omics provides the consensus-scored MARCHF9 profile across patient tissues and cancer cell-line models. MARCHF9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MARCHF9 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, MARCHF9 RNA expression shows 18,132 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where MARCHF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF9 survival associations across molecular data types. MARCHF9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF9 RNA expression–survival associations across cancer types. High MARCHF9 expression shows unfavorable associations in ACC, COAD and LGG, but favorable associations in UVM, OV and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MARCHF9 RNA expression.
This table summarizes MARCHF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MARCHF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF9 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRP, HNSC, READ and STAD. The COAD box plot shows higher MARCHF9 RNA expression in tumor versus normal tissue (log2 FC = +1.474, t-test p < 0.001).
This table shows molecular features associated with MARCHF9 in patient tissues and cancer cell lines. In patient samples, MARCHF9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
